GenturaDx | GenomeWeb

GenturaDx

This article was originally posted on Sept. 12.
Luminex has no plans to acquire any new businesses or companies at this time, its CEO Patrick Balthrop said at an investment conference last week.

Luminex this week provided investors with additional details regarding the planned expansion of its molecular diagnostics business to tap into the laboratory-developed test market and to serve customers seeking a platform with higher throughput and lower multiplexing than Luminex

Luminex this week provided investors with an update on its molecular diagnostics pipeline, including the integration of recently acquired GenturaDx and its sample-to-answer testing platform and the market uptake and opportunity for its xTAG Gastrointestinal Pathogen Panel.

NEW YORK (GenomeWeb News) – Luminex today disclosed the finances of GenturaDx, a molecular diagnostic test firm that it acquired for $50 million during the summer.

NEW YORK (GenomeWeb News) – Luminex has completed the acquisition of molecular diagnostics firm GenturaDx for $50 million in cash plus potential additional consideration based on milestones and/or product revenue performance.

Luminex this week made a play for the low- to mid-volume molecular diagnostic testing market by when it announced that it is acquiring privately held molecular diagnostics developer GenturaDx for $50 million.

NEW YORK (GenomeWeb News) – Luminex has signed a definitive agreement to acquire molecular diagnostics firm GenturaDx for $50 million in cash and potential additional consideration based on milestones and/or product revenue performance.

Gen-Probe has been awarded US Patent No. 8,145,435, "Real-time amplification and monitoring system incorporating vector-based algorithm for analyzing polynucleotide-containing samples."

ArcticZymes has named Brent Spoth as business development manager for the Americas.

PrimeraDx announced the appointment of David Heffelfinger as VP of engineering and systems development.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.